Featured Research

from universities, journals, and other organizations

Protein levels could predict if bowel cancer patients will benefit from Avastin

Date:
October 23, 2012
Source:
University of Bristol
Summary:
Comparing levels of specific proteins that the drug Avastin targets could identify patients with advanced bowel cancer who will benefit from the treatment, according to new research.

Comparing levels of specific proteins that the drug Avastin targets could identify patients with advanced bowel cancer who will benefit from the treatment, according to research published in Clinical Cancer Research on October 23.

Avastin, or Bevacizumab, has been shown to increase survival from bowel cancer in around ten to 15 per cent of patients, but it has been impossible to predict who will benefit.

Avastin works by targeting and blocking the VEGF-A protein, two major forms of which are VEGF165 and VEGF165b.

VEGF165 helps cancers to grow new blood vessels, so they can get food and oxygen from the blood -- all cancers need a blood supply to be able to survive and grow. Its sister protein, VEGF165b, has the opposite effect and acts as a brake on this growth.

Cancer Research UK funded scientists at the University of Bristol looked at the effect Avastin had on patients with different levels of VEGF165b and compared this with patients who were not given the drug at all.

Those with low levels of VEGF165b survived three months longer without the disease progressing compared to patients not treated with Avastin. But patients with higher levels of the protein saw no benefit from Avastin and survived no longer than as those who were not given the drug.

Avastin blocks both forms of VEGF-A, so in patients with lower levels of VEGF165b more Avastin may be available to block the blood vessel promoting protein VEGF165, eventually starving the cancer.

Professor David Bates, lead researcher from the University of Bristol's School of Physiology and Pharmacology, said: "Avastin has shown great potential for a minority of people with bowel cancer, but it's been impossible to predict who will benefit from the drug. Currently, Avastin is not approved by NICE for patients with advanced bowel cancer because they feel that the benefit to an unknown minority of patients does not justify the cost of treatment.

"We now need to look at cancer samples from a larger group of patients about to start taking Avastin and determine if the amount of VEGF165b can accurately identify those patients that will benefit and so potentially open a new treatment option for some people with advanced bowel cancer."

Bowel cancer is the third most common cancer in the UK with around 41,000 people diagnosed each year. Survival rates have doubled over the last 40 years but 16,000 people still die from the disease.

Dr Julie Sharp, senior science information manager at Cancer Research UK, added: "New targeted treatments can be hugely beneficial for certain patients, depending on the characteristics of their tumour. But, we don't always know who these patients are. This work takes researchers a step closer to developing a suitable test so doctors can give Avastin to those people it will really make a difference to."


Story Source:

The above story is based on materials provided by University of Bristol. Note: Materials may be edited for content and length.


Cite This Page:

University of Bristol. "Protein levels could predict if bowel cancer patients will benefit from Avastin." ScienceDaily. ScienceDaily, 23 October 2012. <www.sciencedaily.com/releases/2012/10/121023134807.htm>.
University of Bristol. (2012, October 23). Protein levels could predict if bowel cancer patients will benefit from Avastin. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2012/10/121023134807.htm
University of Bristol. "Protein levels could predict if bowel cancer patients will benefit from Avastin." ScienceDaily. www.sciencedaily.com/releases/2012/10/121023134807.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins